Inflammation

, Volume 35, Issue 3, pp 1138–1143

The Efficiency of a Urotensin II Antagonist in an Experimental Lung Fibrosis Model

  • Ahmet Mesut Onat
  • Ibrahim Halil Turkbeyler
  • Yavuz Pehlivan
  • Tuncer Demir
  • Davut Sinan Kaplan
  • Seyithan Taysi
  • Ali Osman Ceribasi
  • Ediz Tutar
  • Bunyamin Kisacik
Article

DOI: 10.1007/s10753-011-9421-6

Cite this article as:
Onat, A.M., Turkbeyler, I.H., Pehlivan, Y. et al. Inflammation (2012) 35: 1138. doi:10.1007/s10753-011-9421-6

Abstract

Pulmonary fibrosis is a chronic disease. Urotensin II (U-II) is a new peptide with angiogenic and profibrotic features. Therefore, we aim to evaluate the antagonism of U-II with palosuran in an animal model and plan to measure U-II, endothelin-1 (ET-1), and transforming growth factor-β1 (TGF-β1) and their association with lung fibrosis. Thirty Wistar male rats were used in the study and were divided into three groups: group 1, control; group 2, bleomycin-induced lung fibrosis group; and group 3, bleomycin-induced lung fibrosis with treatment palosuran group. U-II level (nanograms per milliliter) was 2.957 ± 0.159 in group1, 3.188 ± 0.122 in group 2, and 2.970 ± 0.165 in group 3 (p = 0.002). The ET-1 level (picograms per milliliter) was 4.486 ± 0.376 in group 1, 9.086 ± 1.850 in group 2, and 4.486 ± 0.376 in group 3 (p < 0.001). The TGF-β1 (nanograms per milliliter) level was 73.143 ± 9.96 in group 1, 84.81 ± 4.73 in group 2, and 77.86 ± 5.77 in group 3 (p = 0.006). Finally, the fibrosis score was 0.7 ± 0.48 in group 1, 4.4 ± 1.34 in group 2, and 3.2 ± 0.63 in group 3 (p < 0.001). There is a statistically significant positive relationship between fibrosis scores and the UT-II, ET-1, and TGF-β1 levels of the experimental lung fibrosis model. We believe U-II is an important mediator in lung fibrosis models, and its antagonism with palosuran could be a new treatment choice for interstitial lung fibrosis, but further studies need to be conducted to verify the findings of the current study.

KEY WORDS

lung fibrosisendothelin-1urotensin II antagonistpalosuran

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ahmet Mesut Onat
    • 1
  • Ibrahim Halil Turkbeyler
    • 2
  • Yavuz Pehlivan
    • 1
    • 3
  • Tuncer Demir
    • 4
  • Davut Sinan Kaplan
    • 4
  • Seyithan Taysi
    • 5
  • Ali Osman Ceribasi
    • 6
  • Ediz Tutar
    • 7
  • Bunyamin Kisacik
    • 1
  1. 1.Department of Rheumatology, Sahinbey Medical Center, School of MedicineGaziantep UniversityGaziantepTurkey
  2. 2.Department of Internal Medicine, Sahinbey Medical Center, School of MedicineGaziantep UniversityGaziantepTurkey
  3. 3.Department of Rheumatology, Sahinbey Medical Center, School of MedicineGaziantep UniversityGaziantepTurkey
  4. 4.Department of Physiology, School of MedicineGaziantep UniversityGaziantepTurkey
  5. 5.Department of Biochemistry, School of MedicineGaziantep UniversityGaziantepTurkey
  6. 6.Department of Pathology, School of VeterinaryFirat UniversityElazigTurkey
  7. 7.Department of Pathology, School of MedicineGaziantep UniversityGaziantepTurkey